OR WAIT null SECS
October 13, 2021
Pacira’s acquisition grants them access to Flexion’s pain management portfolio.
October 12, 2021
AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.
Supernus will acquire Adamas’ Parkinson's disease treatment portfolio through a $400 million acquisition.
October 11, 2021
MilliporeSigma, the U.S. and Canadian Life Science business of Merck KGaA, Darmstadt, Germany, signed an agreement with Cellecta to license its genome-editing tool.
October 08, 2021
The approval of ChemoCentryx’s Tavenos (avacopan) provides a new treatment for active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
AstraZeneca’s tezelpelumab was granted orphan drug designation by FDA for the treatment of eosinophilic esophagitis.
Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.
Pfizer and BioNTech’s request would make them the first vaccine accessible to individuals under the age of 12.
Moderna’s new facility is expected to produce 500 million vaccine doses per year.
October 07, 2021
FDA’s emergency use authorization will double rapid at-home COVID-19 testing capacity.